The Center for Diabetes and Endocrine Care

Fort Lauderdale, Florida 33312

2 studies enrolling now · 12 studies all time

What they study most

Cardiovascular Disease, Cortisol Excess, Cushing Disease, Cushing Syndrome, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Endogenous Cushing's Syndrome, Graves Disease, Graves' Disease

Studies at this site

• A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease — Recruiting now
• Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) — Recruiting now
• Eversense® Non-adjunctive Use Post Approval Study — Running, not enrolling
• Open-label Treatment in Cushing's Syndrome — Completed
• Post Approval Study of the Eversense® Continuous Glucose Monitoring — Completed
• Gan & Lee Insulin Glargine Target Type (1) Evaluating Research — Completed
• A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. — Completed
• Gan & Lee Insulin Glargine Target Type (2) Evaluating Research — Completed
• Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro — Withdrawn before enrolling
• This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses) — Completed
• Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early